Medicare

Local Pharmacies on the Brink, New Survey Reveals

Retrieved on: 
Tuesday, February 27, 2024

The rule is intended to give pharmacies and patients more transparency on drug pricing.

Key Points: 
  • The rule is intended to give pharmacies and patients more transparency on drug pricing.
  • According to the new NCPA survey, 32 percent of all respondents say they are considering closing their doors in 2024 because of the cash crunch.
  • Increased vertical and horizontal consolidation of PBMs and health plans has caused severe inequities to pharmacies and Medicare Part D beneficiaries alike.
  • Community pharmacies are rooted in the communities where they are located and are among America’s most accessible health care providers.

Common Ground Healthcare cooperative pursues affiliation with CareSource

Retrieved on: 
Tuesday, February 27, 2024

CareSource was founded in Dayton, Ohio in 1989 with a mission to transform health care for members in government-sponsored health care programs.

Key Points: 
  • CareSource was founded in Dayton, Ohio in 1989 with a mission to transform health care for members in government-sponsored health care programs.
  • The company’s commitment to improving lives helped CareSource grow quickly to become one of the largest Medicaid Managed Care Plans in the country.
  • CareSource was also nationally recognized by Fortune Magazine in 2023 as one of America’s best places to work in health care.
  • “I believe CareSource will help take us to the next level, which our members and our provider partners deserve,” Mahaffey said.

Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced its financial results for the three months and full year ended December 31, 2023.

Key Points: 
  • Gross margin was 35.5% during the fourth quarter of 2023, compared to 30.9% in the fourth quarter of 2022.
  • Total operating expenses in the fourth quarter of 2023 were $8.6 million, compared to $5.7 million in the fourth quarter of 2022.
  • Excluding the impact of AlterG, operating expenses were $5.4 million in the fourth quarter of 2023, compared to $5.7 million in the fourth quarter of 2023, down $0.3 million, or -4%.
  • Operating loss in the fourth quarter of 2023 was $6.1 million, compared to $5.0 million in the fourth quarter of 2022.

Mobileye Global Inc. investors: Please contact the Portnoy Law Firm to recover your losses; March 18, 2024 deadline

Retrieved on: 
Tuesday, February 27, 2024

LOS ANGELES, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mobileye Global Inc. (NASDAQ: MBLY) investors that a lawsuit was filed on behalf of investors that purchased Mobileye securities between January 26, 2023 and January 3, 2024 inclusive (the “Class Period”).

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • Mobileye attributed this to supply chain challenges in 2021 and 2022, along with lower-than-expected production at certain OEMs in 2023.
  • The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing.

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

Retrieved on: 
Tuesday, February 27, 2024

Launched OGSIVEO in the U.S. and achieved net product revenue of $5.4 million in the first partial quarter of the launch.

Key Points: 
  • Launched OGSIVEO in the U.S. and achieved net product revenue of $5.4 million in the first partial quarter of the launch.
  • Presented additional patient-reported outcome data from the Phase 3 DeFi trial at the 2023 Connective Tissue Oncology Society Annual Meeting.
  • Revenues: OGSIVEO net product revenues were $5.4 million in the fourth quarter of 2023, the first partial quarter of the U.S. launch.
  • Cash Position: Cash, cash equivalents and marketable securities were $662.6 million as of December 31, 2023.

Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024

The Company will host a conference call on February 27, 2024, at 8:00 am ET to discuss these results and management’s outlook for future financial and operational performance.

Key Points: 
  • The Company will host a conference call on February 27, 2024, at 8:00 am ET to discuss these results and management’s outlook for future financial and operational performance.
  • The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call under the same link.
  • If you wish to participate in the live conference call, then please go to https://register.vevent.com/register/BI4f3d577f597e4536bc0d4c9f66d273ff to preregister and obtain your dial-in number and passcode.
  • This news release and the financial statements contained herein, and the slide presentation for the webcast, are also available on the Privia Health Investor Relations website at ir.priviahealth.com.

Simple HealthKit Launches Expanded Kidney Health Evaluation for Patients with Diabetes (KED) Program to Help Payers Improve Patient Health, Boost STAR Ratings & Meet HEDIS Measures

Retrieved on: 
Monday, February 26, 2024

At the heart of the program is Simple HealthKit’s new Expanded Kidney Health Test, which evaluates kidney function and kidney damage, and is available via in-clinic or at-home settings.

Key Points: 
  • At the heart of the program is Simple HealthKit’s new Expanded Kidney Health Test, which evaluates kidney function and kidney damage, and is available via in-clinic or at-home settings.
  • Diabetes is the leading cause of chronic kidney disease (CKD)—about 1 in 3 adults with diabetes have CKD.
  • At-home kidney health tests could drastically reduce Medicare expenditures associated with CKD, while boosting Star Ratings, and satisfying KED HEDIS® measures for MY2024.
  • Simple HealthKit already works with multiple payers across the U.S. including government agencies, universities and private healthcare plans like Imperial Health.

Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2023 Results; Sets 2024 Guidance

Retrieved on: 
Monday, February 26, 2024

The strategic initiatives the Company implemented in 2023 will further catalyze our growth engine as we enter into 2024.

Key Points: 
  • The strategic initiatives the Company implemented in 2023 will further catalyze our growth engine as we enter into 2024.
  • With the momentum of these results, we are reaffirming our 2024 Adjusted EBITDA guidance to be greater than $495 million and setting 2024 revenue guidance to be greater than $3.0 billion.”
    Revenue for the fourth quarter of 2023 increased 4.0% to $735.4 million from $707.1 million for the fourth quarter of 2022.
  • For the fourth quarter of 2023, the Company’s Adjusted EBITDA was $142.3 million, compared to $120.8 million for the same period last year.
  • Cash flows from operating activities was $62.6 million for the fourth quarter 2023, compared to $7.2 million for the same period in 2022.

Kessler Topaz Meltzer & Check, LLP Reminds Amplitude, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Retrieved on: 
Monday, February 26, 2024

The action charges Amplitude with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Amplitude with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Amplitude’ s materially misleading statements and omissions to the public, Amplitude’ s investors have suffered significant losses.
  • Our securities fraud litigators are regularly recognized as leaders in the field as well as the firm itself which is continuously awarded for the successful results we’ve achieved.
  • Kessler Topaz Meltzer & Check, LLP encourages Amplitude investors who have suffered significant losses to contact the firm directly to acquire more information.

WellSpan Health and Evangelical Community Hospital Announce Definitive Agreement to Combine Health Systems

Retrieved on: 
Monday, February 26, 2024

York, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- WellSpan Health and Evangelical Community Hospital have entered into a definitive agreement to enhance community-based health care across the region.

Key Points: 
  • York, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- WellSpan Health and Evangelical Community Hospital have entered into a definitive agreement to enhance community-based health care across the region.
  • Pending regulatory approval, Evangelical Community Hospital will become WellSpan Evangelical Community Hospital on or about July 1, 2024.
  • We’re excited to build on that commitment with Evangelical,” said Roxanna Gapstur Ph.D., R.N., president and CEO of WellSpan Health.
  • A separate philanthropic foundation will be created as a community pathway for hospital support, similar to WellSpan’s other hospital foundations.